Skip to main content
Signal8

Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026

$BIIBPress releaseOct 29, 2026, 6:59 AM ET

Biogen announced it will present new data across its Alzheimer's disease portfolio at the CTAD conference on November 16-19, 2026 in Boston. Headline items include 96-week long-term extension data and additional 76-week biomarker and clinical data from the Phase 2 CELIA study of the tau-targeting ASO diranersen, plus five-year Clarity AD open-label extension and three-year real-world LEADER data for lecanemab.

Key figures

Lte data weeks
96
Celia enrollment
416
Celia biomarker data weeks
76
Lecanemab approved countries
53

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    BIIB: Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026 — AI Analysis | Signal8